PASG (Passage Bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PASG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Lynx1 Capital Management LP | 10%+ Owner | Buy | — | — |
| 2026-05-21 | Sandip Kapadia | Director | A | — | — |
| 2026-05-21 | Dolan Sondhi | Director | A | — | — |
| 2026-05-21 | Athena Countouriotis | Director | A | — | — |
| 2026-05-21 | Thomas Richard Kassberg | Director | A | — | — |
| 2026-05-21 | Derrell Porter | Director | A | — | — |
| 2026-05-21 | MAXINE GOWEN | Director | A | — | — |
| 2026-03-18 | William Chou | PRESIDENT AND CEO | A | — | — |
| 2026-03-18 | Kathleen Borthwick | CFO | A | — | — |
| 2026-01-12 | William Chou | PRESIDENT AND CEO | MIXED | — | — |
| 2026-01-12 | Kathleen Borthwick | CFO | MIXED | — | — |
| 2025-12-29 | William Chou | PRESIDENT AND CEO | A | — | — |
| 2025-12-29 | Kathleen Borthwick | CFO | A | — | — |
| 2025-09-15 | Lynx1 Capital Management LP | 10%+ Owner | Buy | — | — |
| 2025-07-24 | Lynx1 Capital Management LP | 10%+ Owner | Buy | — | — |
| 2025-06-26 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2025-05-30 | Derrell Porter | Director | A | — | — |
| 2025-05-30 | Dolan Sondhi | Director | A | — | — |
| 2025-05-30 | Sandip Kapadia | Director | A | — | — |
| 2025-05-30 | MAXINE GOWEN | Director | A | — | — |
| 2025-05-30 | Thomas Richard Kassberg | Director | A | — | — |
| 2025-05-30 | Saqib Islam | Director | A | — | — |
| 2025-05-30 | Athena Countouriotis | Director | A | — | — |
| 2025-04-24 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2025-04-17 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2025-03-18 | Kathleen Borthwick | CFO | A | — | — |
| 2025-03-18 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | — | — |
| 2025-03-18 | William Chou | PRESIDENT AND CEO | A | — | — |
| 2025-02-12 | Kathleen Borthwick | CFO | MIXED | — | — |
| 2025-01-14 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2025-01-08 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2024-12-31 | Lynx1 Capital Management LP | 10%+ Owner | Buy | — | — |
| 2024-12-26 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2024-12-11 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2024-12-06 | ORBIMED ADVISORS LLC | 10%+ Owner | Sell | — | — |
| 2024-11-27 | Lynx1 Capital Management LP | 10%+ Owner | Buy | — | — |
| 2024-10-02 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | — | — |
| 2024-10-02 | Thomas Richard Kassberg | Director | A | — | — |
| 2024-09-23 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2024-09-18 | OrbiMed Capital GP VII LLC | 10%+ Owner | Sell | — | — |
| 2024-05-23 | Sandip Kapadia | Director | A | — | — |
| 2024-05-23 | MAXINE GOWEN | Director | A | — | — |
| 2024-05-23 | Saqib Islam | Director | A | — | — |
| 2024-05-23 | Athena Countouriotis | Director | A | — | — |
| 2024-05-23 | Dolan Sondhi | Director | A | — | — |
| 2024-05-23 | Derrell Porter | Director | A | — | — |
| 2024-03-19 | William Chou | PRESIDENT AND CEO | A | — | — |
| 2024-03-19 | Kathleen Borthwick | CFO | A | — | — |
| 2024-03-19 | Mark S Forman | CHIEF MEDICAL OFFICER | A | — | — |
| 2024-03-19 | Edgar B. Cale | GC & CORPORATE SECRETARY | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 673,759 | — |
| — | 10%+ Owner | 385,918 | — |
| — | 10%+ Owner | 313,980 | — |
| — | 10%+ Owner | 247,989 | — |
| — | 10%+ Owner | 148,862 | — |
| — | Director | 148,862 | — |
| — | Director | 103,472 | — |
| — | Director | 35,418 | — |
| — | Director | 32,807 | — |
| — | Chief Operating Officer | 18,618 | — |
| — | PRESIDENT AND CEO | 10,600 | — |
| — | CFO | 5,402 | — |
| — | GC & CORPORATE SECRETARY | 3,090 | — |
| — | CHIEF MEDICAL OFFICER | 2,432 | — |
| — | Chief Financial Officer | 1,772 | — |
| — | Chief Technical Officer | 1,435 | — |
| — | Director | 945 | — |
| — | CEO and President | 799 | — |
| — | Chief Financial Officer | 273 | — |
| — | Director | 250 | — |
| — | Chief Commercial Officer | 250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PASG quote page; the site-wide leaderboard is on the insider transactions hub.